The second extracellular loop of α 2A-adrenoceptors contributes to the binding of yohimbine analogues

British Journal of Pharmacology

Volumn 151, Issue 8, 2007, Pages 1293-1304

  Laurila, J M M ^a   Xhaard, H ^b   Ruuskanen, J O ^a   Rantanen, M J M ^a   Karlsson, H K ^a   Johnson, M S ^b   Scheinin, M ^a,c  

^a UNIVERSITY OF TURKU   (Finland)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

^c HOSPITAL DISTRICT OF SOUTHWEST FINLAND   (Finland)

Author keywords

2A adrenoceptor; GPCR; Ligand binding; Rauwolscine; Receptor models; RS 79948 197; Second extracellular loop; Yohimbine

Indexed keywords

1,3,4,5',6,6',7,12B OCTAHYDRO 1',3' DIMETHYL 2H SPIRO[BENZO[B]FURO[2,3 A]QUINOLIZINE 2,4' PYRIMIDINE] 2' ONE; 12 ETHYLSULFONYL 5,8,8A,9,10,11,12,12A,13,13A DECAHYDRO 3 METHOXY 6H ISOQUINO[2,1 G][1,6]NAPHTHYRIDINE; 2 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 4,4 DIMETHYL 1,3(2H,4H) ISOQUINOLINEDIONE; 2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR; AMINO ACID; ATIPAMEZOLE; CHLORPROMAZINE; DOPAMINE; DOXAZOSIN; IMIDAZOLE; LIGAND; NEUROLEPTIC AGENT; NORADRENALIN; PRAZOSIN; RAUWOLSCINE; YOHIMBINE; YOHIMBINE DERIVATIVE;

AMINO ACID ANALYSIS; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; HUMAN VERSUS ANIMAL COMPARISON; MOLECULAR MODEL; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; ISOQUINOLINES; LIGANDS; MICE; MODELS, MOLECULAR; MUTATION; NAPHTHYRIDINES; QUINOLIZINES; RECEPTORS, ADRENERGIC, ALPHA-2; SPECIES SPECIFICITY; YOHIMBINE;

EID: 34547883463     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707330     Document Type: Article

References (48)

1. Altman JD, Trendelenberg AU, MacMillan L, Bernstein D, Limbird L, Starke K et al. (1999). Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. Mol Pharmacol 56: 154-161.
2. Ballesteros JA, Weinstein H (1995). Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. In: Sealfon SC (ed). Receptor Molecular Biology. Academic Press Inc.: San Diego, pp 366-427.
3. Bissantz C, Bernard P, Hibert M, Rognan D (2003). Protein-based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets? Proteins 50: 5-25.
4. Blaxall HS, Heck DA, Bylund DB (1993). Molecular determinants of the alpha-2D adrenergic receptor subtype. Life Sci 53: 255-259.
5. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 7: 248-254.
6. Bylund DB (2005). Alpha-2 adrenoceptor subtypes: are more better? Br J Pharmacol 144: 159-160.
7. 3H]rauwolscine. J Neurochem 51: 81-86.
8. Cockcroft V, Frang H, Pihlavisto M, Marjamäki A, Scheinin M (2000). Ligand recognition of serine-cysteine amino acid exchanges in transmembrane domain 5 of alpha2-adrenergic receptors by UK 14,304. J Neurochem 74: 1705-1710.
9. Cheng Y, Prusoff WH (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
10. Dixon RA, Sigal IS, Candelore MR, Register RB, Scattergood W, Rands E et al. (1987). Structural features required for ligand binding to the beta-adrenergic receptor. EMBO J 11: 3269-3275.
11. Eason MG, Jacinto MT, Theiss CT, Liget SB (1994). The palmitoylated cysteine of the cytoplasmic tail of alpha 2A-adrenergic receptors confers subtype-specific agonist-promoted downregulation. Proc Natl Acad Sci USA 91: 11178-11182.
12. Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamäki A (2001). Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem 276: 31279-31284.
13. 3H]RX821002 as radioligands. Biochim Biophys Acta 1266: 207-214.
14. Johnson MS, Overington JP (1993). A structural basis for sequence comparisons. An evaluation of scoring methodologies. J Mol Biol 233: 716-738.
15. Lan H, Durand CJ, Teeter MM, Neve KA (2006). Structural determinants of pharmacological specificity between D(1) and D(2) dopamine receptors. Mol Pharmacol 69: 185-194.
16. Li J, Edwards PC, Burghammer M, Villa C, Schertler GF (2004). Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol 343: 1409-1438.
17. Link R, Daunt D, Brash G, Chruscinski A, Kobilka B (1992). Cloning of two mouse genes encoding alpha 2-adrenergic receptor subtypes and identification of a single amino acid in the mouse alpha 2-C10 homolog responsible for an interspecies variation in antagonist binding. Mol Pharmacol 42: 16-27.
18. Link RE, Desai K, Hein L, Stevens ME, Chruscinski A, Bernstein D et al. (1996). Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtype b and c. Science 273: 803-805.
19. MacDonald E, Kobilka BK, Scheinin M (1997). Gene targeting - homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol Sci 18: 211-219.
20. MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE (1996). Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science 273: 801-803.
21. Marjamäki A, Pihlavisto M, Cockcroft V, Heinonen P, Savola JM, Scheinin M (1998). Chloroethylclonidine binds irreversibly to exposed cysteines in the fifth membrane-spanning domain of the human alpha2A-adrenergic receptor. Mol Pharmacol 53: 370-376.
22. Michel AD, Loury DN, Whiting RL (1989). Differences between the alpha 2-adrenoceptor in rat submaxillary gland and the alpha 2A-and alpha 2B-adrenoceptor subtypes. Br J Pharmacol 98: 890-897.
23. Molderings GJ, Bonisch H, Bruss M, Likungu J, Gothert M (2000). Species-specific pharmacological properties of human alpha(2A)-adrenoceptors. Hypertension 36: 405-410.
24. Nyrönen T, Pihlavisto M, Peltonen JM, Hoffrén AM, Varis M, Salminen T et al. (2001). Molecular mechanism for agonist-promoted alpha(2A)-adrenoceptor activation by norepinephrine and epinephrine. Mol Pharmacol 59: 1343-1354.
25. Okada T, Fujiyoshi Y, Silow M, Navarro J, Landau EM, Shichida Y (2002). Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc Natl Acad Sci USA 99: 5982-5987.
26. O'Rourke MF, Iversen LJ, Lomasney JW, Bylund DB (1994). Species orthologs of the alpha-2A adrenergic receptor: the pharmacological properties of the bovine and rat receptors differ from the human and porcine receptors. J Pharmacol Exp Ther 271: 735-740.
27. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA et al. (2000). Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289: 739-745.
28. Peltonen JM, Nyrönen T, Wurster S, Pihlavisto M, Hoffrén AM, Xhaard H et al. (2003). Molecular mechanisms of ligand-receptor interactions in transmembrane domain V of the alpha2A-adrenoceptor. Br J Pharmacol 140: 347-358.
29. Richman JG, Brady AE, Wang Q, Hensel JL, Colbran RJ, Limbird LE (2001). Agonist-regulated interaction between alpha2-adrenergic receptors and spinophilin. J Biol Chem 276: 15003-15008.
30. Ruffolo Jr RR, Hieble JP (1994). Alpha-adrenoceptors. Pharmacol Ther 61: 1-64.
31. Ruuskanen JO, Laurila J, Xhaard H, Rantanen VV, Vuoriluoto K, Wurster S et al. (2005). Conserved structural, pharmacological and functional properties among the three human and five zebrafish alpha 2-adrenoceptors. Br J Pharmacol 144: 165-177.
32. Ruuskanen JO, Xhaard H, Marjamäki A, Salaneck E, Salminen T, Yan YL et al. (2004). Identification of duplicated fourth alpha2-adrenergic receptor subtype by cloning and mapping of five receptor genes in zebrafish. Mol Biol Evol 21: 14-28.
33. Sali A, Blundell TL (1993). Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234: 779-815.
34. Salminen T, Varis M, Nyrönen T, Pihlavisto M, Hoffrén AM, Lönnberg T et al. (1999). Three-dimensional models of alpha(2A)-adrenergic receptor complexes provide a structural explanation for ligand binding. J Biol Chem 274: 23405-23413.
35. Schwartz TW (1994). Locating ligand-binding sites in 7TM receptors by protein engineering. Curr Opin Biotechnol 4: 434-444.
36. Shi L, Javitch JA (2004). The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. Proc Natl Acad Sci USA 101: 440-445.
37. Simonneaux V, Ebadi M, Bylund DB (1991). Identification and characterization of alpha 2D-adrenergic receptors in bovine pineal gland. Mol Pharmacol 40: 234-241.
38. Strader CD, Sigal IS, Register RB, Candelore MR, Rands E, Dixon RA (1987). Identification of residues required for ligand binding to the beta-adrenergic receptor. Proc Natl Acad Sci USA 84: 4384-4388.
39. Surgand JS, Rodrigo J, Kellenberger E, Rognan D (2006). A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins 62: 509-538.
40. Svensson SP, Bailey TJ, Porter AC, Richman JG, Regan JW (1996). Heterologous expression of the cloned guinea pig alpha 2A, alpha 2B, and alpha 2C adrenoceptor subtypes. Radioligand binding and functional coupling to a CAMP-responsive reporter gene. Biochem Pharmacol 51: 291-300.
41. Teller DC, Okada T, Behnke CA, Palczewski K, Stenkamp RE (2001). Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry 40: 7761-7772.
42. Trumpp-Kallmeyer S, Hoflack J, Bruinvels A, Hibert M (1992). Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. J Med Chem 35: 3448-3462.
43. 3H]RS79948-197 binding to human, rat, guinea pig and pig alpha2A-, alpha2B- and alpha2C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine. Eur J Pharmacol 343: 93-101.
44. Wong SK, Slaughter C, Ruoho AE, Ross EM (1988). The catecholamine binding site of the beta-adrenergic receptor is formed by juxtaposed membrane-spanning domains. J Biol Chem 263: 7925-7928.
45. 1D receptor: importance of the second extracellular loop and fifth transmembrane domain in antagonist binding. Mol Pharmacol 54: 1088-1096.
46. Xhaard H, Nyrönen T, Rantanen VV, Ruuskanen JO, Laurila J, Salminen T et al. (2005). Model structures of alpha-2 adrenoceptors in complex with automatically docked antagonist ligands raise the possibility of interactions dissimilar from agonist ligands. J Struct Biol 150: 126-143.
47. Xhaard H, Rantanen VV, Nyrönen T, Johnson MS (2006). Molecular evolution of adrenoceptors and dopamine receptors: implications for the binding of catecholamines. J Med Chem 49: 1706-1719.
48. Zhao MM, Hwa J, Perez DM (1996). Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding. Mol Pharmacol 50: 1118-1126.